美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

38.46

-0.2688-0.69%

成交量：2.53萬

成交額：97.37萬

市值：3.53億

市盈率：- -

高：38.80

開：38.80

低：38.30

收：38.73

52周最高：39.80

52周最低：30.66

股本：917.00萬

流通股本：917.00萬

量比：1.37

換手率：0.28%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%

DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月

創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用

迪哲醫藥：比瑞替尼II期研究發表，ORR達47.6%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.46,"timestamp":1789492240324,"preClose":38.7288,"halted":0,"volume":25349,"delay":0,"changeRate":-0.006940571357749241,"floatShares":9170000,"shares":9170000,"eps":0,"marketStatus":"交易中","change":-0.2688,"latestTime":"09-15 13:14:23 EDT","open":38.8,"high":38.8,"low":38.3,"amount":973730.503275,"amplitude":0.01291,"askPrice":38.51,"askSize":100,"bidPrice":38.41,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.7288,"sharesOutstanding":12900000,"nav":38.64,"aum":354328800,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.8756,"preClose":38.7288,"latestTime":"19:30 EDT","volume":254,"amount":9872.1379,"timestamp":1789428600910,"change":0.1468,"changeRate":0.00379,"amplitude":0.003759},"volumeRatio":1.365705,"impliedVol":0.2275,"impliedVolPercentile":0.7861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.365705,"shares":9170000,"dividePrice":0,"high":38.8,"amplitude":0.01291,"preClose":38.7288,"low":38.3,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.46,"committee":0.714286,"eps":0,"divideRate":0,"volume":25349,"delay":0,"ttmEps":0,"open":38.8,"prevYearClose":34.16,"prevWeekClose":38.8541,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.9958,"twentyDayClose":38.09,"sixtyDayClose":37.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667658657","title":"港股異動 | 映恩生物-B升逾9%，DB-1311聯用Pumitamig WCLC摘要披露，一線SCLC ORR達92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658657?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"sh","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","LU2543165471.USD","ORR","HK0000252152.HKD","09606","BK4588","VXUS","HK0000500386.USD","BK1161","HK0000252160.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667645276","title":"DESTINY-Lung04 III期臨床研究顯示，優赫得®一線治療HER2突變晚期非小細胞肺癌患者的中位無進展生存期達14.3個月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667645276","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667645276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:16","pubTimestamp":1789384560,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗组的中位PFS为14.3个月，而帕博利珠单抗联合化疗组为8.3个月。\" 阿斯利康全球执行副总裁、肿瘤研发负责人Susan Galbraith表示：\"DESTINY-Lung04是首项在HER2突变晚期NSCLC患者中，证实PFS优于全球一线标准治疗的III期临床研究。在DESTINY-Lung04临床研究中，德曲妥珠单抗的安全性特征与其已知安全谱总体一致，未发现新的安全性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046853_ZH46853_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE00B19Z4B17.USD","LU0128525929.USD","DCO","LU0432979614.USD","LU2237443465.HKD","LU0566484027.USD","BK4231","IE00B66KJ199.SGD","LU2237443978.SGD","LU2237443895.HKD","ADC","NETL","BK4007","BK4187","CR","ORR","LU2456880835.USD","FXN","PFS","LU2089984988.USD","PXI","LU2236285917.USD","LU2462157665.USD","LU1829250122.USD","LU0708994859.HKD","LU1267930573.SGD","LU2237443622.USD","ROKT","BK4585","AZNH","BK4568","LU0289739699.SGD","BK4213","LU0058720904.USD","LU0320765992.SGD","LU1559883803.SGD","LU0109394709.USD","LU2417539215.USD","LU0310800379.SGD","BK4588","IE0031619046.USD","IE00B7SZL793.SGD","PR","BK4161","AZN","LU2237443549.SGD","IE00B3T34201.USD","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666798529","title":"創新藥將迎數據催化窗口！OS、PFS、ORR還都分不清楚？速查指南來了！收藏備用","url":"https://stock-news.laohu8.com/highlight/detail?id=2666798529","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666798529?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 19:22","pubTimestamp":1789125720,"startTime":"0","endTime":"0","summary":"创新药重磅提示！就在周六，2026年WCLC将正式开幕，康方生物、石药集团、科伦博泰生物等诸多创新药龙头公司将公布旗下核心产品临床数据。III期达到终点，意味着获批概率大幅提升，属于实质性大利好。临床试验中通常报告“中位OS”，即50%患者存活的时间。FDA加速批准程序允许基于替代终点批准药物，但上市后需完成确证性试验。FDA规定，提交后30天内若无异议，IND自动生效。以优效性为目标的头对头试验证据级别最高。权重数据截至2026.8.31。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-11/doc-inirnhrw8907408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","BK1574","ORR","159992","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583697","title":"迪哲醫藥：比瑞替尼II期研究發表，ORR達47.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583697","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666583697?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:48","pubTimestamp":1788940107,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}